Nuvation Bio’s Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval

All NewsJune 11, 2025

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent